undamentalytics Newsletter

Avalo Therapeutics, Inc. valuation and forecast

Explore the models for Avalo Therapeutics, Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Analyst recommendations

14 analysts, Oct 2026
Buy1286%
Hold214%
Sell00%

Monthly trend

  1. Oct 2026210214
  2. Sep 202621214
  3. Aug 202621315
  4. Jul 202621315

Counts of recommendations published by analysts covering Avalo Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

AVTX valuation questions

How does Fundamentalytics value Avalo Therapeutics, Inc.?
We use the models that fit Avalo Therapeutics, Inc.'s business and available financial data. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved November 1, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Avalo Therapeutics, Inc.

Compare with peers